Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access

Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe

Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA

Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder